STOCKS TELEGRAPH

Tag: LPTX

  • Upcoming New Data Presentation: Leap Therapeutics Inc. (LPTX) Gains After Hours

    On January 18, Leap Therapeutics Inc. (LPTX) announced its upcoming presentation about new positive data from its DisTinGuish study. Consequently, the stock became bullish in the after-hours.

    During regular trading, LPTX stock declined by 4.23% at its closing price of $2.72 with 2.81M shares exchanging. Following the announcement, the stock added 12.50% at $3.06 in the after-hours session on Tuesday.

    The clinical-stage biopharmaceutical company, Leap Therapeutics Inc. has a market capitalization of $250.82 million. Currently, the company has 88.32 million shares outstanding in the market.

    LPTX’s Upcoming Presentation

    On Tuesday, the company announced that it will be presenting new positive data from LPTX DisTinGuish study at the ASCO GI Cancers Symposium. The American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium will be held from January 20-22, 2022. Moreover, for discussing the study results, a conference call will be held with Dr. Samuel Klempner of Harvard Medical School and Massachusetts General Hospital on January 21, 2022.

    DisTinGuish Study

    It is a Phase 2a study of DKN-01 in combination with tislelizumab in patients with inoperable, locally advanced, G/GEJ adenocarcinoma (gastric or gastroesophageal junction cancer). Further, the DKN-01 in the combination is studied as first-line (1L) or second-line (2L) therapy in the patients, with or without chemotherapy. Additionally, the company is conducting the study under an exclusive option and license agreement with BeiGene.

    Furthermore, the study is being conducted in two parts: i) Part A as 1L in HER2- G/GEJ cancer patients and; ii) Part B as 2L in DKK1-high G/GEJ cancer patients.

    The preliminary data from both parts demonstrated encouraging data that support the therapeutic potential of LPTX’s DKN-01. Also, the positive data from the study warrant further study in a randomized clinical trial in 1L G/GEJ cancer patients.

    Other Recent Participations

    Recently, the company also participated in other conferences including i) H.C. Wainwright BioConnect 2022 Conference, ii) 40th Annual J.P. Morgan Healthcare Conference, iii) Piper Sandler 33rd Annual Virtual Healthcare Conference.

    LPTX Financial Data

    On November 12, the company declared its financial results for the third quarter of 2021. According to this, LPTX incurred a net loss of $11.1 million in the third quarter of 2021. Comparatively, the net loss was $7.1 million in the year-ago quarter.

    In addition, in the third quarter of 2021 as well as 2020, the license revenue was the same $0.4 million.

    The company ended the quarter with cash and cash equivalents of $124.8 million.

  • Leap Therapeutics Inc. (LPTX) stock surges high during pre-market trading. Let’s find out why:

    Leap Therapeutics Inc. (NASDAQ: LPTX) stock gained by 3.36% in the last trading close whereas the LPTX stock is surging by 34.96% during the pre-market trading session after Leap Therapeutics has presented the clinical data of DKN-01 on March 22, at the society of Gynecologic oncology 2021 Annual meeting on the issue of  Women’s cancer. Leap Therapeutics is dedicated to the development of targeted and immuno-oncology therapies.

    What is happening?

    At the society of Gynecologic Oncology, Leap therapeutics presented the Phase 2 clinical trial of DKN-01 as a monotherapy in addition with paclitaxel in patients with more complex gynecological malignancies. DKN-01, is the most advanced clinical candidate of LPTX which is a humanized monoclonal antibody that specifically targets the Dickkopf-1 (DKK1) protein that causes the activation of innate immune system in the tumor microenvironment. DKN-01 is currently being tested in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers.

    Rebecca Arend, MSPH, the associate professor in University of Alabama at Birmingham O’Neal Comprehensive Cancer Center said that DKN-01 has shown promising response and also a monotherapy complete response for more than 2 years now as well as long-lasting reduction of tumor as both, a single agent and combined with paclitaxel in the study’s chronic gynecologic cancer patients. She also added that in the patients with high level of DKK1, the disease control rate and chances of survival were the highest which shows the efficiency of DKN-01 because the same group of people showed extremely unsatisfactory results towards other therapies. Upon trials it has been concluded that DKN-01 is extremely well tolerated among patients.

    Conclusion

    This positive development in Leap Therapeutics will expectedly help them to show successful results in 2021. This is definitely a great advancement in the field of pharmaceuticals that will act as a catalyst for LPTX stock price. With this growing pace, Investors will be comfortable in making long-term investments.